Amyloid plaque and neurofibrillary tangle deposition is an essential component for accurate modeling...

Migration, Crosslink

📖

Amyloid plaque and neurofibrillary tangle deposition is an essential component for accurate modeling...

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-hypotheses-amyloid-plaque-neurofibr

📖 Wiki Page

hypothesis2082 wordssynced 2026-04-02

Amyloid Plaque and Neurofibrillary Tangle Deposition in Alzheimer's Disease Mouse Models

Mechanistic Model

flowchart TD subgraph Initiation A["Abeta Production APP->BACE->gamma-secretase"] --> B["Abeta Oligomerization Soluble toxic species"] end subgraph Amyloid Cascade B --> C["Plaque Deposition Insoluble aggregates"] C --> D["Synaptic Dysfunction LTP impairment, spine loss"] D --> E["Neuronal Hyperexcitability Network hyperactivity"] end subgraph Tau Pathology E --> F["Tau Phosphorylation Kinase overactivation"] F --> G["Tau Misfolding Conformational change"] G --> H["NFT Formation Paired helical filaments"] end subgraph Neurodegeneration H --> I["Neuronal Loss Apoptosis, necrosis"] I --> J["Network Breakdown Connectivity disruption"] J --> K["Cognitive Decline Memory, executive"] end subgraph Inflammation C --> L["Microglial Activation TREM2 signaling"] L --> M["Pro-inflammatory Cytokines IL-1beta, TNF-alpha"] M --> F end style A fill:#0a1929,stroke:#333,color:#e0e0e0 style B fill:#3a3000,stroke:#333,color:#e0e0e0 style H fill:#3b1114,stroke:#333,color:#e0e0e0 style K fill:#3b1114,stroke:#333,color:#e0e0e0 style L fill:#0e2e10,stroke:#333,color:#e0e0e0

Overview

...

Amyloid Plaque and Neurofibrillary Tangle Deposition in Alzheimer's Disease Mouse Models

Mechanistic Model

Mermaid diagram (expand to render)

Overview

This hypothesis addresses the critical role of amyloid plaque and neurofibrillary tangle (NFT) co-deposition in accurately modeling Alzheimer's disease (AD) in preclinical models. The presence of both pathological hallmarks is considered essential for creating mouse models that faithfully recapitulate key features of human AD neuropathology, including the complex interplay between amyloid and tau pathology that drives disease progression. [@c2016]

Type: Mechanistic Proposal

Confidence Level: Strong

Testability Score: 10/10

Therapeutic Potential Score: 8/10

Related Diseases: [Alzheimer's Disease](/diseases/alzheimers-disease)

Evidence Assessment

Evidence Type Breakdown

| Evidence Type | Strength | Key Findings |
|---------------|----------|--------------|
| Genetic | Strong | APP, PSEN1, PSEN2 mutations cause familial AD; APOE ε4 increases Aβ accumulation and reduces clearance |
| Biochemical | Strong | Aβ42/Aβ40 ratio determines aggregation propensity; soluble oligomers more toxic than fibrils |
| Neuropathological | Strong | Human AD brain shows Aβ plaques and NFT co-localization; Braak staging correlates with clinical severity |
| Animal Models | Strong | APP/PS1, 5xFAD models develop plaques; triple transgenic models show amyloid-tau interactions |
| Clinical Trials | Moderate | Anti-amyloid antibodies reduce plaques but show modest cognitive benefits (lecanemab, donanemab) |
| Imaging | Strong | Amyloid and tau PET demonstrate progressive pathology; ligand binding correlates with cognitive decline |

Key Supporting Studies

Hardy & Selkoe (2002) — Established the amyloid cascade hypothesis framework and identified key evidence supporting Aβ as initiating event. [@hardy2002]

Busche & Hyman (2020) — Demonstrated synergistic interactions between amyloid and tau at the synaptic level, showing that Aβ induces neuronal hyperexcitability that accelerates tau pathology. [@busche2020]

Huang et al. (2022) — Showed that amyloid and tau co-deposition in mouse models recapitulates human pattern; identified mechanisms of cross-seeding between pathologies. [@huang2022]

Jack et al. (2010) — Proposed the dynamic biomarkers cascade model showing the temporal sequence of AD biomarkers from Aβ accumulation through tau-mediated neurodegeneration. [@jack2010]

De Strooper & Karran (2023) — Reviewed the cellular phase of AD, emphasizing that Aβ triggers a self-propagating tauopathy that becomes independent of amyloid. [@de strooper2023]

Key Challenges and Contradictions

Clinical Trial Disappointments: Anti-amyloid antibodies (solanezumab, crenezumab) failed in late-stage trials despite reducing Aβ burden, suggesting Aβ alone is insufficient for disease modification.

Pathology Without Dementia: Many elderly individuals have substantial amyloid and tau pathology without cognitive impairment, indicating protective factors or compensatory mechanisms.

Tau-Independent Amyloid Effects: Some data suggests Aβ can cause neurodegeneration independent of tau, complicating the cascade model.

Timing Question: Whether Aβ initiates pathology in sporadic AD remains unclear, as many patients show tau pathology without clear amyloid trigger.

Pathological Background

Amyloid Plaques

Amyloid plaques are extracellular aggregates of amyloid-beta (Aβ) peptides, derived from the [amyloid precursor protein](/entities/app-protein) (APP) through proteolytic cleavage by [β-secretase](/entities/bace1) (BACE1) and [γ-secretase](/entities/gamma-secretase). The accumulation of Aβ42 and Aβ40 peptides into plaques is considered an early event in AD pathogenesis, triggering downstream tau pathology and neuroinflammation. [@hardy2002]

Key Molecular Pathways:

APP Processing: APP can be processed via two pathways:

Amyloidogenic: APP → BACE1 → γ-secretase → Aβ peptides (Aβ40, Aβ42)
Non-amyloidogenic: α-secretase → sAPPα → γ-secretase → p3 peptides

Aβ Aggregation: Aβ monomers aggregate into:

Soluble oligomers — Most toxic species; disrupt synaptic function
Protofibrils — Intermediate aggregation state
Fibrils — Main component of plaques
Plaques — Insoluble deposits; may serve as reservoir of toxic species

Clearance Mechanisms:

Enzymatic degradation — Neprilysin, IDE
Microglial phagocytosis — TREM2-dependent uptake
Perivascular drainage — Vascular clearance
Transport across BBB — LRP1-mediated efflux

Neurofibrillary Tangles

Neurofibrillary tangles are intracellular inclusions composed of hyperphosphorylated [tau protein](/proteins/tau). Tau normally stabilizes microtubules, but when phosphorylated at abnormal sites, it aggregates into paired helical filaments (PHFs) that disrupt neuronal transport and lead to cell death. The progression of NFT pathology follows a predictable pattern in AD, beginning in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and spreading through the [hippocampus](/brain-regions/hippocampus) and neocortex. [@jack2010]

Tau Phosphorylation Biology:

| Kinase | Target Sites | Role in AD |
|--------|--------------|------------|
| GSK-3β | Ser396, Thr231, Ser9 | Primary tau kinase |
| CDK5 | Ser202, Thr205 | Neuron-specific |
| MAPK | Ser396, Ser404 | Stress-responsive |
| JNK | Thr183, Ser202 | Apoptosis-linked |

| Phosphatase | Function | AD Changes |
|-------------|----------|------------|
| PP2A | Major tau phosphatase | Reduced in AD |
| PP1 | Dephosphorylates tau | Activity altered |
| PP5 | Calcium-regulated | Variable changes |

Amyloid-Tau Interaction Mechanisms

Synergistic Pathways

Mermaid diagram (expand to render)

Abeta-Induced Kinase Activation: Abeta oligomers cause neuronal hyperactivity leading to overactivation of tau kinases (GSK-3beta, CDK5)

Tau-Dependent Synaptic Dysfunction: Tau mediates Abeta-induced synaptic loss through mechanisms independent of NFT formation

Microglial Cross-Talk: TREM2 variants that impair microglial clearance lead to increased Abeta and altered tau pathology

Network Propagation: Abeta and tau pathology spread along connected neural networks in a mutually reinforcing manner

Requirements for Accurate Mouse Models

Accurate AD mouse models must replicate key pathological features:

Available Models

| Model | Aβ Pathology | Tau Pathology | Cognitive Deficits | Limitations |
|-------|-------------|----------------|---------------------|--------------|
| APP/PS1 | +++ | + | +++ | No NFT-like pathology |
| 5xFAD | +++ | ++ | +++ | No classical NFT |
| 3xTg-AD | ++ | ++ | +++ | Complex genetics |
| APP/TTA | +++ | ++ | +++ | Inducible expression |
| P301S | - | +++ | +++ | No amyloid |
| rTg4518 | - | +++ | +++ | No amyloid |
| 5xFAD/TE4 | +++ | +++ | +++ | Dual pathology model |

Model Requirements:

Amyloid deposition: APP/PS1, 5xFAD, and APP/TTA models show robust plaque formation
Tau pathology: Models expressing human mutant MAPT develop NFT-like pathology
Neuroinflammation: Microglial activation surrounding plaques
Synaptic loss: Reduced synaptic markers and impaired LTP mechanisms
Cognitive deficits: Spatial memory and learning impairments
Amyloid-tau interaction: Dual-pathology models show synergistic effects

Genetic Risk Factors

While most mouse models use familial AD (FAD) mutations, genetic risk factors for sporadic AD include:

Major Genetic Risk Factors

| Gene | Variant | Effect on Aβ | Effect on Tau | Risk |
|------|---------|--------------|---------------|------|
| [APOE](/proteins/apoe) | ε4 | ↑ Accumulation, ↓ clearance | ↑ Propagation | 3-4x |
| [TREM2](/proteins/trem2) | R47H | ↓ Phagocytosis | Altered response | 2-3x |
| CLU | C-allele | ↑ Aggregation | Variable | 1.2x |
| PICALM | Various | ↑ Endocytosis | Variable | 1.1x |
| MS4A | Various | ↓ CSF Aβ42 | ↓ CSF p-tau | Variable |
| CD33 | C-allele | ↑ Microglial retention | Variable | 1.2x |

These risk factors suggest that sporadic AD may involve mechanisms beyond simple Aβ accumulation, including microglial dysfunction, lipid metabolism alterations, and immune system modulation. [@bettel2021]

Therapeutic Implications

Understanding the relationship between amyloid and tau has critical implications for therapy:

Current Therapeutic Approaches

| Approach | Target | Status | Efficacy | Limitations |
|----------|--------|--------|----------|-------------|
| Lecanemab | Aβ plaques | Approved | Modest (27% slowing) | ARIA, late-stage only |
| Donanemab | Aβ plaques | Approved | Modest | ARIA, limited population |
| Anti-tau antibodies | Tau oligomers | Phase 1-2 | Pending | BBB penetration |
| Tau kinase inhibitors | GSK-3β, CDK5 | Preclinical | Unknown | Toxicity |
| Tau aggregation inhibitors | PHF formation | Preclinical | Unknown | Bioavailability |

Combination Strategies

Dual-target immunotherapy: Targeting both Aβ and tau simultaneously may provide superior benefits over single-target approaches. [@mallik2023]

Sequential targeting: Remove amyloid early, then target tau before widespread spread occurs.

Network protection: Maintain functional connectivity while reducing pathology burden.

Timing is critical: Intervention before significant tau spread appears necessary for meaningful clinical benefit.

Biomarker Development

| Biomarker | Measures | Utility | Status |
|-----------|----------|---------|--------|
| Amyloid PET | Plaque burden | Diagnostic, monitoring | Validated |
| Tau PET | NFT burden | Diagnostic, staging | Validated |
| CSF Aβ42 | Soluble Aβ | Diagnostic | Validated |
| CSF p-tau181/217 | Tau pathology | Diagnostic, monitoring | Validated |
| Plasma p-tau217 | Tau pathology | Screening | Emerging |

Key Entities

Proteins and Pathways

[Amyloid plaques](/proteins/amyloid-plaques) — Extracellular Aβ aggregates
[Neurofibrillary tangles](/mechanisms/neurofibrillary-tangles) — Intracellular tau aggregates
[Amyloid-beta](/proteins/amyloid-beta) — Peptide cleavage product of APP
[Tau protein](/proteins/tau) — Microtubule-stabilizing protein
[APP gene](/genes/app) — Amyloid precursor protein
[MAPT gene](/genes/mapt) — Tau-encoding gene
[BACE1 gene](/genes/bace1) — β-secretase
[PSEN1](/genes/psen1)/[PSEN2](/genes/psen2) — γ-secretase components

Cell Types and Systems

[Microglia](/cell-types/microglia-neuroinflammation) — Immune cells that clear Aβ
[Neurons](/entities/neurons) — Primary targets of tau pathology
[Synapses](/entities/synapses) — Dysfunctional in both pathologies
[Blood-brain barrier](/entities/blood-brain-barrier) — Therapeutic delivery challenge

[Amyloid cascade hypothesis](/mechanisms/amyloid-cascade) — Original Aβ-centric model
[Tau pathology mechanisms](/mechanisms/tau-pathology) — Tau phosphorylation and aggregation
[Neuroinflammation](/mechanisms/neuroinflammation) — Microglial contributions
[Long-term potentiation](/mechanisms/long-term-potentiation) — Synaptic dysfunction

Experimental Approaches

In Vitro Models

iPSC-derived neurons — Patient-specific models with AD mutations

Brain organoids — 3D cultures showing amyloid-tau interactions

Transwell co-cultures — Neuron-microglia interaction studies

Protein aggregation assays — Biochemical characterization of seeding

In Vivo Models

Standard models: APP/PS1, 5xFAD for amyloid; P301S for tau

Dual-pathology models: Crossbreeding for combined pathology

Humanized models: Knock-in of human APOE variants

Inducible models: Temporal control of pathology expression

Readouts

| Outcome | Method | Relevance |
|---------|--------|-----------|
| Plaque burden | Histology, PET | Amyloid pathology |
| NFT burden | Histology, Tau PET | Tau pathology |
| Synaptic markers | IHC, electrophysiology | Functional status |
| Behavior | Morris water maze, Y-maze | Cognitive function |
| Network activity | LFP, calcium imaging | Circuit dysfunction |

Current Status

This hypothesis is supported by multiple lines of evidence from the literature. The requirement for dual amyloid-tau pathology in accurate AD models is well-established, with many groups developing dual-pathology models to better recapitulate human disease. However, recent clinical trials targeting amyloid have shown that removing plaques alone may not halt cognitive decline, highlighting the importance of understanding tau pathology and other contributing factors. The field is moving toward combination therapies targeting both pathologies simultaneously.

Future Directions

Improved dual-pathology models: Better mouse models that recapitulate both pathologies and their interactions

Biomarker-driven trials: Use tau PET to select patients and monitor treatment response

Combination approaches: Target amyloid and tau in parallel

Precision medicine: Match therapies to genetic subtypes and biomarker profiles

References

[C. Dirk Keene et al. (2016)](https://doi.org/10.3402/pba.v6.32397) — Discusses the necessity of amyloid and tau pathology for AD modeling

[Hardy & Selkoe (2002)](https://doi.org/10.1126/science.1072994) — The amyloid cascade hypothesis in AD

[Jack et al. (2010)](https://doi.org/10.1016/j.jalz.2010.01.001) — Relationships between biomarkers in AD

[Busche & Hyman (2020)](https://doi.org/10.1172/JCI135437) — Synergy between amyloid and tau in AD

[Huang et al. (2022)](https://doi.org/10.1038/s41586-022-04440-5) — Amyloid and tau co-deposition in mouse models

[Sevigny J, et al. (2016)](https://doi.org/10.1038/nature19323) — Aducanumab reduces Aβ plaques

[Bettens K, et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34145442/) — Genetic insights in AD

[Mallik S, et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36933762/) — Dual-targeting immunotherapy

[Chen X, et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37158899/) — Tau propagation in 5xFAD mice

[De Strooper B, Karran E. (2023)](https://pubmed.ncbi.nlm.nih.gov/36810344/) — The cellular phase of AD

Pathway Diagram

The following diagram shows the key molecular relationships involving Amyloid plaque and neurofibrillary tangle deposition is an essential component for accurate modeling... discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

hypotheses-amyloid-plaque-neurofibrillary-tangle-depositi

▸Metadataorigin_type: v1_polymorphic_backfill

slug	hypotheses-amyloid-plaque-neurofibrillary-tangle-depositi
kg_node_id	None
entity_type	hypothesis
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-754ecdce863e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'hypotheses-amyloid-plaque-neurofibrillary-tangle-depositi'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

488

Outgoing

562

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Amyloid plaque and neurofibrillary tangle deposition is an essential component for accurate modeling...

Amyloid Plaque and Neurofibrillary Tangle Deposition in Alzheimer's Disease Mouse Models

Mechanistic Model

Overview

Amyloid Plaque and Neurofibrillary Tangle Deposition in Alzheimer's Disease Mouse Models

Mechanistic Model

Overview

Evidence Assessment

Evidence Type Breakdown

Key Supporting Studies

Key Challenges and Contradictions

Pathological Background

Amyloid Plaques

Neurofibrillary Tangles

Amyloid-Tau Interaction Mechanisms

Synergistic Pathways

Requirements for Accurate Mouse Models

Available Models

Genetic Risk Factors

Major Genetic Risk Factors

Therapeutic Implications

Current Therapeutic Approaches

Combination Strategies

Biomarker Development

Key Entities

Proteins and Pathways

Cell Types and Systems

Experimental Approaches

In Vitro Models

In Vivo Models

Readouts

Current Status

Future Directions

See Also

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Amyloid plaque and neurofibrillary tangle deposition is an essential component for accurate modeling...

Amyloid Plaque and Neurofibrillary Tangle Deposition in Alzheimer's Disease Mouse Models

Mechanistic Model

Overview

Amyloid Plaque and Neurofibrillary Tangle Deposition in Alzheimer's Disease Mouse Models

Mechanistic Model

Overview

Evidence Assessment

Evidence Type Breakdown

Key Supporting Studies

Key Challenges and Contradictions

Pathological Background

Amyloid Plaques

Neurofibrillary Tangles

Amyloid-Tau Interaction Mechanisms

Synergistic Pathways

Requirements for Accurate Mouse Models

Available Models

Genetic Risk Factors

Major Genetic Risk Factors

Therapeutic Implications

Current Therapeutic Approaches

Combination Strategies

Biomarker Development

Key Entities

Proteins and Pathways

Cell Types and Systems

Related Mechanisms

Experimental Approaches

In Vitro Models

In Vivo Models

Readouts

Current Status

Future Directions

See Also

References

Pathway Diagram

💬 Discussion